Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JAB-3312 · 1 trial · 7 indications
Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-3312.
Measurements of MTD (i.e. the highest dose of JAB-3312 associated with the occurrence of Dose Limiting Toxicities (DLTs) in \<33% of patients) or the RP2D (i.e. the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)
| Arm | Type | Description |
|---|---|---|
| JAB-3312 | EXPERIMENTAL | JAB-3312 will be administered orally once daily in 21 days treatment cycles. |
| Name | Type | Description |
|---|---|---|
| JAB-3312 | DRUG | JAB-3312 will be supplied as 0.25 mg, 1.0 mg and 4.0 mg capsules. |
Inclusion Criteria: 1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. 3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progresse...
Top 20 of 84 competitors
JAB-3312 is an investigational small molecule being studied for the treatment of non-small cell lung cancer. It is also being evaluated in other advanced solid tumors, including colorectal cancer, pancreatic ductal carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and breast cancer.
JAB-3312 is being developed by ArriVent BioPharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVBP. The drug is currently in Phase 1 clinical development.
JAB-3312 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under clinical investigation.
JAB-3312 has been studied in one completed Phase 1 clinical trial, NCT04121286, titled "A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China." The trial enrolled 17 participants with various advanced solid tumors, including non-small cell lung cancer.
JAB-3312 is not known to have any alternative names. It is a distinct investigational small molecule developed by ArriVent BioPharma, Inc. for the treatment of advanced solid tumors, including non-small cell lung cancer.